Drug intelligence / Profile preview

candesartan + amlodipine

Development stage
Phase 3
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

Candesartan + amlodipine is a fixed-dose combination of two antihypertensive agents used to treat high blood pressure (hypertension). Candesartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the type-1 angiotensin II receptor (AT1), thereby preventing vasoconstriction and aldosterone secretion, which results in lowered blood pressure[4][6]. Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to relaxation of blood vessels and reduced cardiac workload[2][3]. The combination provides complementary mechanisms for lowering blood pressure and may be used when monotherapy with either agent does not achieve adequate control.

Brand names
Unisia
Other names
candesartan cilexetil/amlodipineamlodipine/candesartan cilexetil
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on candesartan + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on candesartan + amlodipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call